(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
Purdue Pharma's deal means money for some victims, end of Purdue company name. Here's what to know- 5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- 10 Hints for an Effective New employee screening
- Rachael Ray is navigating grief this holiday season. She doesn't have time for 'negative energy' on the internet.
- In a first, scientists observe a comet reversing its spin
- Partake in the Outside: Senior-Accommodating Exercises for 2024
- Israel scales back use of top missile interceptors as Iran barrages persist
- Beating Wellbeing Difficulties: Individual Victories in Health
- PHOTO ESSAY: Summer camp for kids with autoimmune diseases
